Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up  by Soto, María Elena et al.
Results in Immunology 5 (2015) 13–22Contents lists available at ScienceDirectResults in Immunologyhttp://d
2211-28
n Corr
E-mjournal homepage: www.elsevier.com/locate/rinimPredictive value of antinuclear antibodies in autoimmune diseases
classiﬁed by clinical criteria: Analytical study in a specialized health
institute, one year follow-up
María Elena Soto a,n, Nidia Hernández-Becerril a, Ada Claudia Perez-Chiney a,
Alfredo Hernández-Rizo a, José Eduardo Telich-Tarriba b, Luis Eduardo Juárez-Orozco c,
Gabriela Melendez d, Rafael Bojalil a,e
a Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
b Universidad Panamericana School of Medicine, Mexico City, Mexico
c Universidad Nacional Autónoma de México, Faculty of Medicine, Mexico City, Mexico
d Department of Cardiovascular Magnetic Resonance, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
e Department of Health Care, Universidad Autónoma Metropolitana-Xochimilco, Mexico City, Mexicoa r t i c l e i n f o
Available online 9 November 2013
Keywords:
Antinuclear antibodies
Generalized rheumatic disease
Clinical criteria
Predictive value.x.doi.org/10.1016/j.rinim.2013.10.003
39/& 2014 The Authors. Published by Elsevie
espondence to: Juan Badiano #1, Col. Seccion
ail address: mesoto50@hotmail.com (M.E. Sota b s t r a c t
Introduction: Determination of antinuclear antibodies (ANA) by indirect immunoﬂuorescence (IIF) is
usually the initial test for the diagnosis of systemic rheumatic diseases (SRD). Assigning predictive values
to positive and negative results of the test is vital because lack of knowledge about ANAs and their
usefulness in classiﬁcation criteria of SRD leads to inappropriate use. Methods: Retrospective study, ANA
tests requested by different specialties, correlation to patients' ﬁnal diagnosis. Results: The prevalence of
autoimmune disease was relatively low in our population yielding a low PPV and a high NPV for the ANA
test. 40% of the patients had no clinical criteria applied prior to test. Coexistence of two or more auto-
immune disorders affects prevalence and predictive values. Conclusion: Application of the test after
careful evaluation for clinical criteria remarkably improves the positive likelihood ratio for the diagnosis.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Immunological assays for the detection of antinuclear anti-
bodies (ANA) are useful and important complementary tools for
the diagnosis and follow-up of patients with autoimmune diseases
[1]. The identiﬁcation of the antigen–antibody coupling is the
common end-point for all techniques; however, several differ-
ences exist as for the utility, sensitivity, speciﬁcity, and predictive
values of each test [1,2].
In general, if a patient presents clinical manifestations of an
autoimmune disease, the ﬁrst test to be requested is ANA detec-
tion by indirect immunoﬂuorescence using HEp-2 cells, due to its
great sensitivity [1,3]. The different possible patterns, the intensity,
and the titers obtained by consecutive dilutions must be carefully
examined. Identiﬁcation of the antigens recognized by the ANA isr B.V. This is an open access article
XVI, Tlalpan 14080, Mexico.
o).further evaluated by more speciﬁc tests such as ELISA, radio-
immunoanalysis (RIA) or electroimmunotransference (EIT) [2,4].
The use of these tests requires knowledge of their fundamental
aspects and also of the clinical classiﬁcation criteria of each dis-
order in order to contribute to an appropriate diagnosis [5,6].
The usefulness of this testing has been evaluated in retro-
spective studies of patients with systemic rheumatic disease
(SRD), and it has been proven that its positive predictive value is
low due to the relatively large amount of false positive results. For
speciﬁc rheumatic diseases, the ANA test yields a positive pre-
dictive value of 11%, a negative predictive value of 97%, and a
sensitivity and speciﬁcity of 42% and 85% respectively [7].
Several physiological and pathological factors might favor the
development of ANA in the non-rheumatic population, such as
pregnancy, advanced age, family history of autoimmune disease,
as well as infectious, cardiovascular or oncological diseases [8–12].
This situation conveys challenges such as interpretative standar-
dization [13].under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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M.E. Soto et al. / Results in Immunology 5 (2015) 13–2214A high percentage of patients with high autoantibodies titers
do not manifest any clinical signs of autoimmune disease. This
may be due to the existence of circulating antigens that are not
routinely tested for, such as those resulting from infectious stimuli,
from multifactorial synthesis or those naturally produced by
CD5þ cells [14]. For this reason, clinicians should pay close
attention to the titers in which the ANAs are reported, taking into
account that in healthy individuals, antibodies should be negative
or can be present in low titers, and that intermediate titers may be
present in non-affected relatives of patients with autoimmune
diseases or in elders with chronic infections or neoplasms
[8,11,12,15].
In Mexico, ANA prevalence has been studied in healthy
individuals and consensus has been reached as to consider positive
a gross mottled pattern in dilutions over 1:160, while homo-
geneous, centromeric, peripheral or centriolar patterns should be
considered positive even in dilutions as low as 1:40 [16].
Their presence can be, nevertheless, due to natural antigens
[14,17,18].
In some instances the recognition of antibodies directed to
known antigens cannot be achieved. This complicates the accurate
measurement of the antibody’s predictive value [19,20].
The objective of the present study was to determine the pre-
dictive values (PPV, NPV) of ANA testing for suspected SDR by
analyzing the pre-test assessment of rheumatologic clinical criteria
as well as post-test diagnosis.2. Methods
We analyzed samples for ANA studies requested to our lab
during a twelve-month period. The tests were selected if they
were performed by IIF in HEp-2 cells (INOVA Diagnostics INC San
Diego USA) and if an initial positive result at a 1:40 dilution led to
successive dilutions. An informed consent was obtained for each
test form each patient.
Furthermore, the presence of speciﬁc auto-antibodies was
evaluated by ELISA (ORGENTEC Diagnostica GmBh Carl-Seiss
Mainz,Germany) using puriﬁed extractable nuclear antigens (ENA)
for Sm, RNP/Sm, SSA/Ro, SSB/LA, Anti-Scl-70, and anti-centromere
as well as crithidia luciliae substrate.
An ANA test was considered to be positive when titers were
superior to the following dilutions: Nuclear pattern:
homogeneous41:40, coarse speckled and ﬁne speckled41:160,
laminar and peripheral41:40. Cell cycle: nucleolar, centromeric,
and centriolar41:40. Cytoplasmic41:80 and micotocondrial4
1:160.
Each patient's clinical ﬁle was reviewed by a qualiﬁed rheu-
matologist to acknowledge, if the suspected diagnosis was
conﬁrmed or if there was an alternative ﬁnal diagnosis. We con-
ﬁrmed form the records the evaluation made for the presence
of diagnostic clinical criteria in each patient. Clinical criteria
considered for each disease the following the guidelines for
diagnosis.
2.1. Statistical analysis
Sample size was calculated by correlation as follows:
n
n
n N1
= ′
+ ′⋅
n
S2
2σ
′ =
where N¼1374, standard error, Se¼0.025, p¼0.18, S2 the
sample variance p(1p)¼(018)(1p)¼(0.18) (0.82)¼0.1476}, s2 is
Table 2
Systemic rheumatic disease probability prior to test antibodies.
Antibodies to speciﬁc antigen With autoimmune disease Without Autoimmune
disease
Pretest probability (speciﬁc
antigen)
Change of the probability after the
test (%)
þ 142 55 197 142/197¼72% (PPV) 15
 71 105 176 105/176¼60% (NPV) 3
Total 213 160 373
S¼(142/213)¼67% E¼(105)/(160)¼66%
Solicitors utilization of clinical
criteria
With autoimmune disease Without autoimmune
disease
Pretest probability (clinical
criteria)
Change of the probability after the
test (%)
þ 167 20 187 167/187¼89% 32
 46 140 186 140/186¼75% 18
Total 213 160 373
S¼167/213¼78% E¼140/160¼88%
The application of clinical criteria appropriate to request the test is 213/373¼57%.
S¼sensibility, E¼speciﬁcity.
Table 3
Complex tables to evaluate both tools for diagnosis of autoimmune diseases (appropriate clinical criteria and speciﬁc auto-antibodies).
Clinical criteria and speciﬁc antibodies With autoimmune disease Without autoimmune disease
Both positive 120 6 127
One positive 69 63 130
Both negative 24 91 116
Total 213 160 373
Effect of locating the cut-off point at different levels
Between one and both positive (WCC) (Spþantibodies) Between one and both negative
120 6 189 69
93 154 24 91
213 160 213 160
S¼57% E¼96% S¼89% E¼57%
S¼sensitivity, E¼speciﬁcity.
M.E. Soto et al. / Results in Immunology 5 (2015) 13–22 15the population variance, (Se)2 (0.025)2¼0.000625.
n
S 0.1476
0.000625
236
2
2σ
′ = =
n
n
n1 /
236
1 236/1374
236
1 0.17176
236
1.17176
201.5
202
Ν
′
+ ′
=
+
=
+
=
=
=
Sample size¼202.
We included a total of 373 samples for this study, tendency
measures with mean and standard deviation were obtained for
variables with parametric distribution. Non-parametric variables
were analyzed with percentages, median and ranges. Statistical
analysis was performed using Spearman’s correlation, Chi-square
and exact Fisher’s test with SPSS version 16 and Epi-info version 6.3. Results
A total of 373 requests for ANA evaluation were received. 299
(80%) corresponded to women and 74 (20%) to men. Mean age was
40715 and 37717 years, respectively.In 364 (83%) samples, nuclear antibodies were found with
dilutions 1:40 and no antibodies were found in 9 cases (2%). In 193
out of the 364 (52%) antibodies against speciﬁc antigens were
found.
Frequency of test requests and use of clinical criteria by each
department from our institution are shown in Table 1.
There was a total of 373 ANA tests performed. In 364 (98%)
patients, antibodies were found in dilutions of 1:40. Out of these,
SRD was conﬁrmed in 213 (57%) cases and it could not be con-
ﬁrmed in 160 (42%).
From the 213 patients with conﬁrmed SRD, in 187 (88%) clinical
criteria were applied prior to the blood test, but only in 167 (78%)
SRD was conﬁrmed. In 20 patients (9%), the clinical criteria were
applied but no autoimmune disease could be diagnosed. 120
individuals (56%) were diagnosed with SRD by both clinical and
laboratory criteria. In 47 cases (22%), clinical criteria were used
prior to requesting the ANA test but no antigen-speciﬁc antibodies
were found; 22 (10%) patients had no clinical criteria applied prior
to requesting the test, but ANAs could be found in high dilutions
and were positive against speciﬁc antigens. Therefore the physi-
cian concluded that the patients had an autoimmune disease.
Finally, there were 24 patients (11%) with no clinical criteria
applied prior to soliciting the ANA test and no antigen-speciﬁc
antibodies were found, however, they presented IIF patterns
compatible with autoimmune disease on in high titers.
No autoimmune disease was found in 160 patients. In 6 (4%) of
them, clinical criteria were applied prior to soliciting the ANA test,
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M.E. Soto et al. / Results in Immunology 5 (2015) 13–2216but antibodies were found only in dilutions of 1:40 with antigen-
speciﬁc antibodies, and in 49 patients (31%) no clinical criteria
were applied and the antibodies were found only in low ANA titers
and antigen-speciﬁc antibodies. Also, from these 160 patients, 91
(57%) had not previously met the mentioned clinical criteria
according to the suspected SRD.
These also corresponded mainly to patients with heart or kid-
ney disease.
Dilutions that predominated were 1:40 although there was
some percentage of antibodies in high titers. Even an antigen-
speciﬁc antibody could be found in 8 cases; in these, the attending
physicians applied their clinical judgment and discarded SRD.
Regardless if they presented speciﬁcity towards an antigen or not,
when the criteria were applied SRD was demonstrated in 167
patients (78%) while SRD could only be diagnosed in 46 (22%)
when no criteria were used.
No SRD was found in 141 (88%) of the requests for ANA test in
which no clinical criteria were applied compared to 19 (12%) in the
group in which clinical criteria were used. This difference achieved
statistical signiﬁcance with an OR of 26 (95% CI 14–50, po0.0001).
This analysis strongly supports the application of clinical criteria
prior to the request of antibody testing in patients in whom
autoimmune disease is suspected.
The pretest probability of the antigen-speciﬁc antibody test is
of 57%. Whenever clinical criteria are applied, we observed an
improvement of 32%. Nevertheless, when the antibody test was
used to conﬁrm SRD without the use of clinical criteria this value
diminished to 15% as shown in Table 2.
Further analysis of the information revealed that when clinical
criteria and speciﬁc antibodies are present, we achieve a sensi-
tivity of 57% and a speciﬁcity of 96%; when one or both are
negative we get an increase in sensitivity but a loss in speciﬁcity.
We evaluated the effect of various combinations of these results in
Tables 3 and 4
The aforementioned improvement in the post-test likelihood
ratio results should be observed every time considering both tools
(clinical criteria and speciﬁc antinuclear antibody testing) are not
independent for the diagnosis of autoimmune disease but usually
sequential.
Pre-test probability is 0.57
0.57
1 0.57
1.3
−
=
The likelihood ratio for stand-alone testing and their combined
utility is shown in Table 5, in panel A we see the that pre-test
likelihood for a patient with suspected autoimmune disease when
a test for antigen-speciﬁc antibodies is requested is 1.94; the post-
test probability with an antigen-speciﬁc antibody can be calcu-
lated as follows:
1.94
1.94 1
65% Probabilitypost test
+
= −
Calculating the post-test likelihood ratio when clinical criteria
were used to classify the disease we obtain a result of 3.55 (Panel
B) and a post-test probability of 78%.
3.55
3.55 1
78% Probabilitypost test
+
= −
Panel C shows the result from combining both assessments against
the application of only one evaluation (clinical or serological).
As presented in Table 6, Panel A (patients with autoimmune
disease were¼213), sensitivity was 72% when clinical criteria were
used prior to antigen-speciﬁc antibodies (T-tasa FP) while it only
was 48% when they were not applied and antibody testing was
performed directly.
Table 5
Likelihood ratio for each test.
(a) Speciﬁc-antigen antibodies
Antibodies for speciﬁc antigen With autoimmune disease Without autoimmune disease Likelihoood ratio
Number Proportion Number Proportion
þ 142 142/213¼0.66 55 55/(160¼0.34 0.66/(0.34¼1.94
 71 71/230¼0.30 105 105/160¼0.65 0.30/0.65¼0.46
Total 213 160
(b) Clinical criteria
Classiﬁcation according to criteria With autoimmune disease Without autoimmune disease Likelihood ratio
Number Proportion Number Proportion
þ 167 167/213¼0.78 20 20/160¼0.34 0.78/0.22¼3.55
 46 46/213¼0.22 140 140/160¼0.88 0.30/0.65¼0.39
Total 213 160
(c) Effect of different combinations of speciﬁc antibodies and clinical criteria over the diagnostic workup for SRD
Number Proportion Number Proportion Likelihood ratio
Clinical criteria and speciﬁc antibodies positive 120 120/213¼0.56 6 6/160¼0.037 0.56/0.037¼15.02
One or both negative 93 93/213¼0.44 154 154/160¼0.96 0.44/0.96¼0.45
Total 213 160
M.E. Soto et al. / Results in Immunology 5 (2015) 13–22 17Both tests are independent (in Panel B) (patients without
autoimmune disease¼160), the speciﬁcity for not having auto-
immune disease was of 65% when the clinical criteria were
negative or not used. However, when the test was negative and
clinical criteria had been used, the speciﬁcity of ANA was 70% in
this series. In patients in whom antigen-speciﬁc antibodies are
found, the probability to diagnose them by clinical classiﬁcation
criteria is high while patients with a negative antibody test have a
higher probability of not presenting any clinical manifestations.
This supposed concordance should be further evaluated in larger
series.
As shown in Table 7 panel a, the likelihood ratio to ﬁnd an
autoimmune disease is of 14.97 when both clinical criteria and the
ANA test for speciﬁc antigens yield positive results; a repeated
ANA test would not signiﬁcantly increase the likelihood ratio.
As shown in Table 7 panel b, clinical criteria as a stand-alone
tool (LRþ¼6.24) and the study of ANA against speciﬁc antigens
(LRþ¼2.4) when positive results in a high LR of 6.242.4¼14.97;
likewise, the likelihood ratio when both tests are positive, starting
form ANA against speciﬁc antigens as a stand-alone tool
(LRþ¼1.94) and clinical criteria (LRþ¼7.72) when positive
results in a similar LR, 1.947.72¼14.97. Therefore, the decision to
request an antigen-speciﬁc antibody test can become more
complex.
In this study we also described the frequency of ANA, speciﬁ-
city for speciﬁc antigens, and type of nuclear pattern and their
relationship with SRD. These results are shown in Table 8.
Equally rare patterns such as pattern NuMA antibodies were
found in 7 cases (2%), out of which 5 were women and 3 men, with
a mean age of 33 (28–64) for women and 52 (21–57) for men. Two
of themwere diagnosed with secondary APS, one with SLE plus AS,
another one with SLE plus limited systemic sclerosis, one with
rheumatoid arthritis and Sjogren's syndrome, one with ANCA-
associated vasculitis and pulmonary thromboembolism, and a last
one with atrial tachycardia plus pulmonary arterial hypertension.
Two females presented PCNA antibodies; one was diagnosed
with Takayasu arteritis and the other one with SLE plus dilated
myocardiopathy. Two cases were reported as having antibodies
against proliferating cells.In non-rheumatic diseases we found anti-DNA antibodies, 3% in
patients with cardiopathy, 33% in those with hypothyroidism and
13% in nephropathies not associated with SLE. Predictive values of
the tests in relationship with clinical phenotype of SRD are shown
in Table 9.
The frequency of different patterns of antibodies documented
in this sample were: discrete speckled (DS) 179 (48%), DS- cen-
tromere 8 (2%), DS-NuMA 3 (0.8%), DS-Na, DS-Jo, DS-mitochon-
drial, DS-nucleolar (N) and DS-homogeneous patterns were pre-
sent in 0.3% each. Homogeneous pattern (H) in 109 (29%), both H
and N in 3 (0.8%), H-speckled in 1 (0.3%); Coarse speckled in (CS)
17 (5%), CS-NuMA 4 (1%), speckled 2 (0.5%), cytoplasm 1 (0.3%).
Homogeneous, DS and CS patterns were all observed in high titers
(Fig. 1).
Thirty-ﬁve (22%) patients without autoimmune disease pre-
sented ANA in 1:40 dilutions, but none were observed in dilutions
over 1:320.
In cases with SRD, ANA could be found in dilutions over 1:320
in 199 (57%) compared to those without autoimmune disease 44
(26%), OR 3.45 (CI 95%, 2.19–5.50), and in dilutions between
1:2560 and 5120 71 (39%) in SLE, scleroderma, mixed connective
tissue disease, overlap, Sjogren’s syndrome and rheumatoid
arthritis plus systemic lupus erythematous. Even though they
were observed in non-autoimmune diseases, this percentage was
lower: 12 (8%), OR 5.88 (CI 95%, 2.95–11.94) (Fig. 1a–h).4. Discussion
It is known that positive and negative predictive values for any
test are dependent upon the disease's prevalence, with false
positive results increasing in those samples in which the disease
has a low prevalence, therefore decreasing the test's positive
predictive value [7].
Healthy subject, people with non-autoimmune diseases and
those with a family history of autoimmune disease present a high
percentage of antibodies in low titers [21,22].
Our series reveals that the predictive value of the test is low,
and that it is lower if proper clinical criteria are not applied when
Table 6
Evaluation of the combination of positive results on speciﬁc antibodies and utilization of clinical criteria for the diagnosis of autoimmune disease.
Panel A: Patients with autoimmune disease
Positive speciﬁc antigen antibodies Sensitivity of speciﬁc antigen antibodies (false positive ratio)
Positive Negative
With clinical criteria 120 47 167 With clinical criteria (þ) 120/167¼72%
Without clinical criteria 22 24 46 Without clinical criteria () 22/46¼48%
Total 142 71 213 160 142/213¼67%
Sensitivity of speciﬁc antigen antibodies (1-true positive ratio)
When speciﬁc antibodies (þ) When speciﬁc antibodies () Total
120/142¼85% 47/71¼66% 167/213¼78%
Panel B: Without autoimmune disease
Positive speciﬁc antigen antibodies Sensitivity of speciﬁc antigen antibodies (false positive ratio)
Positive Negative
With clinical criteria 6 14 20 With clinical criteria (þ) 14/20¼70%
Without clinical criteria 49 91 140 Without clinical criteria () 91/140¼65%
Total 55 105 160 160 105/160¼65%
Sensitivity of speciﬁc antigen antibodies (1-true positive ratio)
When speciﬁc antibodies (þ) When speciﬁc antibodies () total
49/55¼89% 91/105¼87% 140/160¼87%
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Table 7
(a) Likehood ratios when two converging tools for autoimmune disease are posi-
tive. (b) Likelihood ratios for SRD diagnosis.
(a)
Autoimmune disease Likelihood ratio
Present Absent
Both positive tool
(clinical criteria CC
and speciﬁc ANA)
120 (56%) 6 (3.7%) 0.56/
0.038¼14.97
0.44/0.96¼0.46
One or both 47 14
þ22 þ49
þ24 þ91
– –
93 (44%) 154 (96%)
Total 213 (100%) 160 (100%
(b)
Positive Likelihood Ratio (L.R.þ)
Clinical criteria AAN against
speciﬁc antigen
Stand-alone test 1(0.78/
(10.87))¼6.24
0.66/(10.66)¼
1.94
When the other test
was positive
(0.85/
(10.89))¼7.72
0.72/(10.70)¼
2.4
M.E. Soto et al. / Results in Immunology 5 (2015) 13–22 19requesting the test [21]. Positive antibodies in low titers may lead
to confusion when trying to establish a diagnosis, and can become
problematic when they are found at higher titers.
It is well known that any test such as antibodies against a
speciﬁc antigen conveys false positive and false negative results.Table 8
Frequency of nuclear patterns and antibodies against speciﬁc antigens in several autoim
Disease Antigen Pattern
n SM RNP SSA SSB SCL70 Anti-cen
SLE 43 13 (31) 13 (30) 13 (30) 4 (9) 1 (2) 1(2)
RAþSLE 8 2 (10) 3 (38) 4(50) 2 (25) 0 0
SLEþAPS 13 1 (5) 2 (15) 4 (30) 0 0 0
SLEþSS 3 0 1 (33) 2 (67) 2 (67) 0 0
Discoid lupus 6 0 1 (17) 0 0 0 1
SLEþhyperthyroidism 2 0 1(50) 0 0 0 0
SLEþhypothyroidism 5 0 0 3 (60) 1 (20) 0 0
RA 17 0 0 1 (6) 0 0 0
RAþSS 10 1 (10) 1 (10) 5 (50) 4 (40) 0
RAþhypothyroidism 1 0 0 0 0 0 0
IJA 5 0 0 0 0 0 0
Scleroderma 16 2 (10) 5 (31) 3(18) 0 1 (6) 3 (19)
SCLþSS 2 0 0 1 (50) 1 (50) 0 1 (50)
SCL 2 0 0 0 0 1 (50) 1(50)
MCTD 5 0 4 (90) 2 (40) 0 1 (14) 0
Overlap 8 1 (5) 2 (25) 2 (25) 0 1 (15) 1(15)
Polymyositis 2 0 0 1 (50) 0 0 1 (50)
Dermatomyositis 1 0 0 0 0 0 0
SS 8 0 0 0 5 (62) 0 0
SSþhypothyroidism 2 0 0 0 0 0 0
Devic syndrome 3 0 0 1 (33) 0 0 0
PAPS 38 0 0 2(5) 0 0 1
Fibromyalgia 7 0 1(3) 0 0 0 1
Cardiopathy 94 1 5 1 1 0 0
Hypothyroidismo 3 0 0 1(3) 0 0 0
Nephropathy 24 0 0 0 0 0 0
Cancer 2 0 0 0 0 0 0
Takayasu’s arteritis 1 0 0 0 0 0 0
APS¼antiphospholipid syndrome, IJA¼ idiopathic juvenile arthritis, MCTD¼mixed conn
arthritis, SCL¼scleroderma, SLE¼systemic erythematous lupus, SS¼systemic sclerodermThis can lead to diagnostic and therapeutic errors by utilizing
measures when they are not required [23,24].
In this analysis, we see that using clinical criteria before
requesting the test provides a considerable improvement in the
diagnostic workup. Antibodies considered to be speciﬁc for SLE,
such as double strand anti-DNA, have been reported as well in
Sjogren's syndrome, dermatomyositis and cutaneous sclerosis
[25–29]. In our series the percentage of SLE patients with positive
ANA was of 49%, with varying frequency ranges from 6% to 50%,
when SLE coexisted with other diseases, and in 90% of patients
with renal damage, a ﬁnding known to bear a worse prognosis
[30–33]. In non-rheumatic diseases we found anti-DNA antibodies
in frequencies similar to those previously reported in the litera-
ture, supporting the idea of the existence of an immunological
alteration in cardiovascular and renal diseases, which might be
explained by previous infections [15,34,35].
Antibodies directed towards ribonucleoproteins (SM, RNP, SSB)
are usually detected in SLE, but not in discoid lupus. Our results
concur with previous literature [31,36]. As for SM antibodies, there
are reported presence of them in 15–40% of cases; we found that
they are present in 30% of cases of SLE when not associated with
other diseases, with ranges that vary from 15% to 50% when
another SRD coexists with SLE or there is damage to a speciﬁc
organ [37,38]. Quite remarkable, elevated ANA titers are important
in the diagnostic of rheumatic diseases, but it is also very impor-
tant to be familiar to each laboratory's cut-off points. Also the type
of pattern of antibodies was found in some cases in close corre-
lation with the presence of some autoimmune diseases. It is
known that antibodies directed against ribonucleoproteins are
associated with connective tissue diseases [39]. An homogeneous
pattern might be proof of reaction against native single or double
stranded DNA and associated with SLE. The centromeric pattern ismune diseases.
tromere Homogeneous Discrete speckled Coarse speckled NUMA PCNA
24 (56) 13 (27) 0 0 1 (2)
5 (63) 6 (75) 0 0 0
4 (31) 6 (43) 0 1 (8) 0
1 (33) 2 (67) 0 0 0
2 (33) 2 (33) 0 0 0
1 (50) 3 (50) 0 0 0
2 (50) 0 0 0 0
10 (59) 2 (12) 0 0 0
3 (30) 5 (50) 0 1 (10) 0
1 (100) 0 0 0 0
3 (60) 2 (40) 0 0 0
1 (6) 7 (44) 0 1 (6) 0
0 1 (50) 0 0 0
1 (50) 1 (50) 0 0 0
0 5 (100) 0 0 0
3 (38) 0 0 0 0
0 0 1 0 0
0 1 (100) 0 0 0
2 (25) 5 (63) 0 0 0
0 1 (50) 0 0 0
0 2 (67) 0 0 0
9 (24) 22 (58) 2 (5) 2 (5) 0
1 (14) 4 (57) 0 0 0
18 (19) 58 (62) 6 (6) 2 (2) 0
2 (67) 1 (33) 0 0 0
3 (13) 9 (38) 4 (17) 0 0
0 1 (50) 0 0 0
0 0 0 0 1
ective tissue disease, PAPS¼primary antiphospholipid syndrome, RA¼rheumatoid
a.
Table 9
Sensibility, speciﬁcity, and predictive values according to autoimmunity disease
and speciﬁcity of antibodﬁes.
SM DNA SSA SSB RNP
SLE S¼35 S¼62 S¼40 S¼25 S¼43
N¼37 E¼99 E¼99 E¼96 E¼99 E¼87
PPV¼93 PPV¼96 PPV¼70 PPV¼91 PPV¼71
NPV¼86 NPV¼88 NPV¼86 NPV¼84 NPV¼87
RAþSLE S¼25 S¼50 S¼50 S¼25 S¼38
N¼8 E¼99 E¼99 E¼94 E¼99 E¼96
PPV¼67 PPV¼80 PPV¼31 PPV¼67 PPV¼30
NPV¼96 NPV¼97 NPV¼97 NPV¼96 NPV¼97
Discoid lupus S¼0 S¼20 S¼0 S¼0 S¼25
N¼6 E¼94 E¼99 E¼94 E¼99 E¼96
PPV¼0 PPV¼50 PPV¼0 PPV¼0 PPV¼13
NPV¼98 NPV¼97 NPV¼96 NPV¼97 NPV¼98
SLEþAPS S¼10 S¼17 S¼33 S¼0 S¼15
N¼11 E¼99 E¼99 E¼94 E¼93 E¼96
PPV¼50 PPV¼67 PPV¼30 PPV¼0 PPV¼22
NPV¼94 NPV¼94 NPV¼95 NPV¼93 NPV¼93
SLEþSS S¼33 S¼33 S¼67 S¼67 S¼33
N¼3 E¼99 E¼99 E¼94 E¼99 E¼96
PPV¼50 PPV¼50 PPV¼18 PPV¼67 PPV¼14
NPV¼99 NPV¼99 NPV¼99 NPV¼99 NPV¼99
SLEþhypothyroidism S¼0 S¼25 S¼75 S¼33 S¼0
N¼4 E¼99 E¼99 E¼94 E¼99 E¼96
PPV¼0 PPV¼50 PPV¼25 PPV¼50 PPV¼0
NPV¼97 NPV¼98 NPV¼79 NPV¼99 NPV¼98
Sjogren’s syndrome S¼0 S¼0 S¼0 S¼38 S¼0
N¼8 E¼99 E¼99 E¼94 E¼97 E¼96
PPV¼0 PPV¼0 PPV¼0 PPV¼75 PPV¼0
NPV¼99 NPV¼96 NPV¼99 NPV¼97 NPV¼95
PAPS S¼0 S¼15 S¼5 S¼0 S¼0
N¼35 E¼99 E¼99 E¼82 E¼82 E¼95
PPV¼0 PPV¼80 PPV¼18 PPV¼0 PPV¼0
NPV¼80 NPV¼85 NPV¼82 NPV¼82 NPV¼82
RA S¼0 S¼20 S¼13 S¼0 S¼0
N¼16 E¼99 E¼99 E¼94 E¼99 E¼95
PPV¼0 PPV¼50 PPV¼18 PPV¼0 PPV¼0
NPV¼99 NPV¼97 NPV¼92 NPV¼91 NPV¼91
IJA S¼0 S¼20 S¼0 S¼0 S¼0
N¼5 E¼99 E¼99 E¼94 E¼99 E¼95
PPV¼0 PPV¼50 PPV¼0 PPV¼0 PPV¼0
NPV¼99 NPV¼97 NPV¼99 NPV¼97 NPV¼91
Scleroderma S¼67 S¼13 S¼23 S¼0 S¼38
N¼12 E¼99 E¼99 E¼95 E¼99 E¼96
PPV¼67 PPV¼50 PPV¼22 PPV¼0 PPV¼41
NPV¼93 NPV¼95 NPV¼94 NPV¼99 NPV¼95
Crest S¼0 S¼0 S¼0 S¼0 S¼60
N¼5 E¼99 E¼99 E¼99 E¼99 E¼96
PPV¼0 PPV¼0 PPV¼0 PPV¼0 PPV¼30
NPV¼80 NPV¼99 NPV¼99 NPV¼99 NPV¼99
APS¼antiphospholipid syndrome, IJA¼ Idiopathic juvenile arthitis, MCTD¼mixed
connective tissue disease, PAPS¼primary antiphospholipid syndrome, RA¼rheu-
matoid arthritis, SCL¼scleroderma, SLE¼systemic lupus erythematosus, SS¼sys-
temic scleroderma, S¼sensitivity, E¼speciﬁcity, PPV¼positive predictive value,
NPV¼negative predictive value.
M.E. Soto et al. / Results in Immunology 5 (2015) 13–2220characteristic of CREST syndrome and those against nucleolar RNA
are associated with SLE and systemic progressive sclerosis [40].
However, other unusual nuclear ANAs are those against the
Nuclear mitotic apparatus (NuMA), which might or might not be
reported accurately depending upon the laboratory's experience
[41]. Their positivity is associated with connective tissue disease,45% corresponding to Sjogren’s syndrome and undifferentiated
connective tissue disease as well as autoimmune diseases against
speciﬁc organs in 17% even though up to 38% have been found in
non-autoimmune diseases [42].
In this study 2% of patients had NuMA, and they were asso-
ciated with primary AS, one of them with optic neuritis and a
possible Devic syndrome. The prevalence of these antibodies and
their clinical signiﬁcance has been previously reported in the lit-
erature [43,44].
Antibodies against the nuclear antigen of proliferative cells
were described over 30 years ago in patients with chronic hepa-
titis B or C, and they have only been found in about 5% of patients
with SLE. Their clinical signiﬁcance has been recently studied in a
metanalysis and they have also been detected in polymyositis,
systemic sclerosis and even healthy individuals. However their
prevalence has not surpassed 2% in any group [45]. In this study,
they were detected in two cases, one of them a 64-year-old
woman with SLE and end stage renal disease, and the second one
in a 23-year-old female with Takayasu arteritis and systemic
arterial hypertension.
The presence of speciﬁc antibodies against cellular components
such as nuclear or cytoplasmic molecules are speciﬁc for some
diseases [46,47] while some other might be completely non-
speciﬁc [48,49]. Moreover other ﬁndings might depend upon a
clinical characteristic of the disease, such as neuropsychiatric
lupus in which anti-p ribosomal antibodies have a 10% prevalence
and were observed in 2% of all patients with SLE [46]. Never-
theless, some antibodies are related with organ speciﬁc alterations
and could be prognostic markers [50]. Commonly, when a non-
rheumatologist specialist requests an ANA test in a patient it is due
to the presence of inﬂammatory signs and symptoms that most
physicians would not overlook. However antibody-testing results
does not consider previous clinical details and speciﬁc diagnosis
becomes quite difﬁcult [51–54].
We were able to conﬁrm the dispersion and utility that these
results have depending upon the clinicians’ specialty, the use of
clinical criteria, and indirectly, the knowledge of some recom-
mendations from guidelines.
We believe that in some cases the severity of the clinical pic-
ture and diagnostic uncertainty may justify requesting for these
tests, however a positive result might turn out to be a confusing
factor and therefore require an interpretation that should into
account, in ﬁrst place, the clinical context.
The use of the test in patients with SRD and a positive result
might lead to a second test. Several studies attempting to obtain
an appropriate use of laboratory tests have been published with
the fair purpose of reducing unnecessary testing [4,55,56].
A non-medical factor, knowledge of the techniques and stan-
dardized procedures, contributes to the optimal use of the test.
Other variables could contribute to the variability of the results
such as ethnicity, the use of clinical criteria, and the coexistence of
several autoimmune diseases or presence of several other
antigens.
On the other hand, when the prevalence of a disease in a
sample is low, positive predictive value tends to be low as well
dictating the need to conﬁrm the result by using a second test.
We found a low prevalence of autoimmune diseases in the
requests of these tests, which were solicited by several specialists
with differing criteria.
From another view, the high percentage of false positives may
be attributed to the fact that only a certain set of antibodies are
routinely tested for, not including other recognized antibodies
such as antihistone, antinucleosomes, CENP-B, CENP-A, CENP-C,
Sp100 protein, PML or NDP53, which could increase the predictive
value of the test [57–62].
Fig. 1. Microphotographs of indirect immunoﬂuorescence of speciﬁc antibodies in Hep2 cells. (a) Cytoplasmic P-ribosomal pattern. (b) NuMA-1 pattern. (c) Centromeric or
discrete speckled pattern. (d) SSA discrete speckled pattern. (e) Homogeneous pattern. (f) Nucleolar with mitochondrial pattern.
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nostic algorithms are applied. This reduces unnecessary ANA tests
and correlating with a better analysis, utilization, and clinical
judgment by the physicians [52,63,64].5. Conclusion
Positive and negative predictive value for the ANA test is low, it
is dependent on the clinical context of the patient and if the
physician relies on clinical criteria for its request. The use of clin-
ical criteria speciﬁc for each probable disease prior to antinuclear
antibodies testing increases the likelihood ratio for the diagnosis
of autoimmune diseases. This also depends upon the phenotype of
the disease and the coexistence of two or more diseases or the
presence of other antigens, which are not routinely tested for in all
laboratories.
The proper use of laboratory tests, in accordance to knowledge
and interdisciplinary communication, signiﬁcantly improves the
diagnostic yield of specialized evaluations.References
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